Click Here for a full summary of the webinar. The seas have remained choppy for the biopharma industry in the early part of 2022. With a bearish capital-raising environment and unaligned valuations to keep deal makers treading water, how biotech’s will remain afloat has become the crux of the sector. In this webinar, Locust Walk and other leading experts in strategic dealmaking and finance discuss the current state of biopharma and what to expect as we settle into 2022.